A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Sponsor
Peking University
Study ID
NCT04616040
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.

Study Details

The trial is a multi-center, open, observational registration study, which aims to evaluate the safety and efficacy of Camrelizumab (anti-PD-1 antibody) in the treatment of Chinese patients with advanced esophageal cancer in the real world.

Key Dates

Start date
Dec 1, 2020
Status verified
Nov 2020
Primary completion
Dec 1, 2023
Completion
Dec 1, 2026

Study Design

Enrollment
1,030 participants (estimated)

Arms

  • Arm: unresectable locally advanced/recurrent or metastatic esophageal cancer

Primary Outcome Measure

Adverse events of Camrelizumab [ Time Frame: an expected average of 24 months ]

Related Studies